Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vorasidenib: First Approval.

Drugs - 1 Oct 2024

Lamb Yvette N

Abstract excerpt

Vorasidenib (VORANIGO®; Servier) is an orally administered, first-in-class, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes being developed for use in IDH-mutant diffuse glioma. Vorasidenib received its first approval on 6 August 2024, in the USA, for the treatment of adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Drug Approval
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Progression-Free Survival

Share to Pyridines

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 39375303
DOI: 10.1007/s40265-024-02097-2
PMCID: PMC11628568

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vorasidenib: First Approval.PMID 39375303Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.Semantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment.Semantic proximity Read ↗

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Semantic proximity Read ↗

Treatment of IDH-mutant glioma in the INDIGO eraSemantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.